To Demonstrate the Relative Bioavailability of Divalproex Sodium 500 mg Delayed Release Tablets Under Fasting Conditions
NCT ID: NCT00913874
Last Updated: 2017-03-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
30 participants
INTERVENTIONAL
2005-10-31
2005-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Double-blind, Placebo-Controlled Divalproex Sodium ER in Bipolar I or Bipolar II Depression
NCT00194116
Study of Divalproex Extended Release Monotherapy in Ambulatory Bipolar Spectrum Disorder With Moderate-to-Severe Hypomania or Mild Mania
NCT00278772
Safety Study of Sodium Divalproate in Bipolar Disorder in Adolescents
NCT00271258
Divalproex Sodium (Depakote) for Explosive Tempers in Adolescents and Adults
NCT00218114
An Inpatient Study of the Effectiveness and Safety of Depakote ER in the Treatment of Mania/Bipolar Disorder
NCT00060905
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Divalproex Sodium 500 mg DR Tablets (Sandoz Inc., USA)
Divalproex Sodium 500 mg DR Tablets (Sandoz Inc., USA)
2
Depakote 500 mg DR Tablets (Abbott Laboratories, USA)
Depakote 500 mg DR Tablets (Abbott Laboratories, USA)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Divalproex Sodium 500 mg DR Tablets (Sandoz Inc., USA)
Depakote 500 mg DR Tablets (Abbott Laboratories, USA)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Treatment for drug or alcohol dependence.
18 Years
50 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sandoz
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Sandoz Inc.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Xueya (Eric) Chen, M.D.
Role: PRINCIPAL_INVESTIGATOR
Pharma Medica Research, Inc.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2005-1049
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.